Why Is Tempest Therapeutics (TPST) Stock Down 25.4% Today?
Key Takeaways
- TPST shares were down roughly 25.4% in Thursday's session, trading near $0.90 after closing at $1.21 the prior day.
- The decline is primarily a sharp profit-taking pullback after the stock surged about 60% on Wednesday.
- Yesterday's rally was fueled by an exclusive option to license Senlang's CD7-targeted in vivo CAR-T platform.
- Secondary pressure stems from dilution concerns linked to a recent private warrant financing and an adjourned shareholder meeting on governance changes.
- Traders are watching whether the stock holds key support levels and for upcoming clinical milestones later in 2026.
Opening Summary
Tempest Therapeutics, Inc. (TPST), a clinical-stage biotechnology company developing in vivo CAR-T therapies and small-molecule oncology treatments, is trading sharply lower on Thursday. Shares were down approximately 25.4% to around $0.90, retreating from a prior-session close of $1.21. The pullback follows an extraordinary single-day rally of roughly 60% on Wednesday, when investors bid up the stock after the company secured an exclusive option to license an in-body CAR-T technology platform from Hebei Senlang Biotechnology. Today's move reflects heavy profit-taking in a highly volatile micro-cap name, compounded by lingering dilution concerns.
Profit-Taking After a Massive Single-Day Rally
The dominant catalyst for today's decline is straightforward: traders are locking in gains after a dramatic surge. On Wednesday, TPST shares more than doubled intraday, touching a high of $1.48 before closing at $1.21, up about 60% from the prior close of $0.7554. Moves of that magnitude in a micro-cap stock frequently trigger a wave of selling the following session as short-term traders and momentum participants book profits. Today's retreat of roughly a quarter of the previous day's gains is consistent with a classic "give-back" pattern rather than a fundamental change in the company's outlook.
The Senlang In Vivo CAR-T Option Agreement
The rally that preceded today's pullback was sparked by a corporate development with genuine strategic significance. TPST announced an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral vector platform and a related pipeline of in vivo CAR-T candidates. The portfolio includes a BCMA/GPRC5D dual-targeting candidate currently in a Phase 1 dose-escalation study for relapsed/refractory multiple myeloma, along with additional programs aimed at hematologic malignancies and autoimmune diseases. The approach is designed to generate CAR-T and CAR-NK cells directly inside patients, avoiding individualized cell collection and external manufacturing. While the announcement validated the company's in vivo CAR-T strategy, the market's initial euphoria has now cooled as investors reassess the early-stage nature of the programs.
Dilution and Financing Overhang
Adding to the downward pressure are capital-structure concerns. The company recently disclosed a private warrant financing, and it adjourned a special shareholder meeting related to governance changes—developments that often signal efforts to raise additional capital. For a clinical-stage biotech with a limited cash runway, equity-linked financings can weigh on shares by diluting existing holders. These factors have contributed to a more cautious tone among investors even as the scientific narrative around the company's CAR-T platform has strengthened.
Market Context and Trading Activity
Trading activity has been exceptionally elevated. Wednesday's session saw volume of roughly 58 million shares, vastly exceeding the stock's typical average daily volume of well under one million shares, and Thursday's turnover has remained heavy as the position unwinds. The outsized volume underscores the speculative, catalyst-driven nature of the move rather than a broad institutional rotation. The action in TPST has been idiosyncratic—driven by company-specific news—and is not closely tracking the broader market or large-cap biotech indices, which have not experienced comparable volatility. From a technical standpoint, the stock's failure to hold near the $1.48 intraday high from Wednesday and its slide back toward the $0.90 area highlights how quickly momentum can reverse in low-priced, high-volatility equities.
What Comes Next for TPST
Looking ahead, investors will be focused on the company's execution across its in vivo CAR-T pipeline. TPST has guided toward advancing its proprietary TPST-4003 candidate into clinical studies, with first patient enrollment and dosing expected in the fourth quarter of 2026, alongside the ongoing evaluation of the Senlang Phase 1 data during the option period. Upcoming earnings, scheduled for early November, and any further updates on financing or capital-raising plans will also be closely watched. Risks remain substantial: the company's programs are early-stage, its cash position is limited, and further dilution remains a possibility. As a result, share-price volatility is likely to persist, and today's pullback serves as a reminder of the two-way risk inherent in speculative biotechnology names.
Trending AI Robots
For investors seeking a more systematic approach to navigating volatile markets, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading tools. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a range of options to explore. Discover the top-performing AI robots today to see how data-driven automation can complement your market analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TPST turns negative, indicating new downward trend
TPST saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 76 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TPST turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
TPST moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TPST crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TPST entered a downward trend on September 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TPST's RSI Oscillator exited the oversold zone, 36 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
TPST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.699) is normal, around the industry mean (26.780). P/E Ratio (0.203) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. TPST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals
Industry Biotechnology
Advertisement